SNYR · Synergy CHC Corp.
The latest filing states the doubt was alleviated.
“Management concluded that the above factors alleviate doubts about the Company's ability to generate enough cash from operations and other available sources to satisfy its obligations for the next twelve months from the issuance date.”View the 10-Q filed May 14, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-06-29 | Fickett Jaime |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The reduction in the exercise price of the Original Option constitutes a material modification and is deemed, for purposes of Section 16, to involve a cancellation of the Original Option and the grant of a new option in its place. The new option vests on the same schedule as the Original Option, as if it had been granted on the Original Grant Date, and expires on the five-year anniversary of the Original Grant Date. One-third (1/3) of this option grant (the "Original Option") vests on the first anniversary of September 18, 2025 (the "Original Grant Date"), and the remaining two-thirds (2/3) vest in equal monthly installments over the twenty-four (24) months thereafter, in each case subject to the reporting person's continued service with the Company. |
Stock Option (right to buy)
|
150,000 |
| 2026-06-29 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Award↑
Filing footnotes — Stock Option (right to buy) (Indirect)
The reduction in the exercise price of the Original Option constitutes a material modification and is deemed, for purposes of Section 16, to involve a cancellation of the Original Option and the grant of a new option in its place. The new option vests on the same schedule as the Original Option, as if it had been granted on the Original Grant Date, and expires on the five-year anniversary of the Original Grant Date. One-third (1/3) of this option grant (the "Original Option") vests on the first anniversary of September 18, 2025 (the "Original Grant Date"), and the remaining two-thirds (2/3) vest in equal monthly installments over the twenty-four (24) months thereafter, in each case subject to the reporting person's continued service with the Company. The reported securities are owned directly by Kenek Brands Inc., which is controlled by the reporting person. The reporting person is the indirect beneficial owner of the reported securities. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
Stock Option (right to buy)
(I)
|
750,000 |
| 2026-06-29 | Baumeler Alfred |
Director, President |
Other↓
Filing footnotes — Stock Option (right to buy) (Direct)
The reduction in the exercise price of the Original Option constitutes a material modification and is deemed, for purposes of Section 16, to involve a cancellation of the Original Option and the grant of a new option in its place. The new option vests on the same schedule as the Original Option, as if it had been granted on the Original Grant Date, and expires on the five-year anniversary of the Original Grant Date. One-third (1/3) of this option grant (the "Original Option") vests on the first anniversary of September 18, 2025 (the "Original Grant Date"), and the remaining two-thirds (2/3) vest in equal monthly installments over the twenty-four (24) months thereafter, in each case subject to the reporting person's continued service with the Company. |
Stock Option (right to buy)
|
150,000 |
| 2026-06-29 | Fickett Jaime |
Chief Financial Officer |
Other↓
Filing footnotes — Stock Option (right to buy) (Direct)
The reduction in the exercise price of the Original Option constitutes a material modification and is deemed, for purposes of Section 16, to involve a cancellation of the Original Option and the grant of a new option in its place. The new option vests on the same schedule as the Original Option, as if it had been granted on the Original Grant Date, and expires on the five-year anniversary of the Original Grant Date. One-third (1/3) of this option grant (the "Original Option") vests on the first anniversary of September 18, 2025 (the "Original Grant Date"), and the remaining two-thirds (2/3) vest in equal monthly installments over the twenty-four (24) months thereafter, in each case subject to the reporting person's continued service with the Company. |
Stock Option (right to buy)
|
150,000 |
| 2026-06-29 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Other↓
Filing footnotes — Stock Option (right to buy) (Indirect)
The reduction in the exercise price of the Original Option constitutes a material modification and is deemed, for purposes of Section 16, to involve a cancellation of the Original Option and the grant of a new option in its place. The new option vests on the same schedule as the Original Option, as if it had been granted on the Original Grant Date, and expires on the five-year anniversary of the Original Grant Date. One-third (1/3) of this option grant (the "Original Option") vests on the first anniversary of September 18, 2025 (the "Original Grant Date"), and the remaining two-thirds (2/3) vest in equal monthly installments over the twenty-four (24) months thereafter, in each case subject to the reporting person's continued service with the Company. The reported securities are owned directly by Kenek Brands Inc., which is controlled by the reporting person. The reporting person is the indirect beneficial owner of the reported securities. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
Stock Option (right to buy)
(I)
|
750,000 |
| 2026-06-29 | Baumeler Alfred |
Director, President |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The reduction in the exercise price of the Original Option constitutes a material modification and is deemed, for purposes of Section 16, to involve a cancellation of the Original Option and the grant of a new option in its place. The new option vests on the same schedule as the Original Option, as if it had been granted on the Original Grant Date, and expires on the five-year anniversary of the Original Grant Date. One-third (1/3) of this option grant (the "Original Option") vests on the first anniversary of September 18, 2025 (the "Original Grant Date"), and the remaining two-thirds (2/3) vest in equal monthly installments over the twenty-four (24) months thereafter, in each case subject to the reporting person's continued service with the Company. |
Stock Option (right to buy)
|
150,000 |
| 2026-04-21 | Kaushal Nitin |
Director |
Award↑
Filing footnotes — Common Stock, par value $0.00001 per share (Direct)
The reported securities are restricted stock units ("RSU"). Each RSU represents a contingent right to receive one share of common stock, par value $0.00001 per share, of Synergy CHC Corp. (the "Issuer"), subject to the conditions set forth in the applicable RSU award agreement and Issuer's 2024 Equity Incentive Plan, as amended. The RSUs vested in full on the grant date. |
Common Stock, par value $0.00001 per share
|
306,433 |
| 2026-04-21 | Thompson Teresa Brigid |
Director |
Award↑
Filing footnotes — Common Stock, par value $0.00001 per share (Direct)
The reported securities are restricted stock units ("RSU"). Each RSU represents a contingent right to receive one share of common stock, par value $0.00001 per share, of Synergy CHC Corp. (the "Issuer"), subject to the conditions set forth in the applicable RSU award agreement and Issuer's 2024 Equity Incentive Plan, as amended. The RSUs vested in full on the grant date. |
Common Stock, par value $0.00001 per share
|
25,824 |
| 2025-09-22 | Thompson Teresa Brigid |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2025-09-18 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Award↑
Filing footnotes — Stock option (right to buy) (Indirect)
One-third (1/3) of this option grant vests on the first anniversary of the date of grant, and the remaining two-thirds (2/3) vest in equal monthly installments over the following twenty-four (24) months, subject to the reporting person's continued service with the Company. The reported securities are owned directly by Kenek Brands Inc., which is controlled by the reporting person. The reporting person is the indirect beneficial owner of the reported securities. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
Stock option (right to buy)
(I)
|
750,000 |
| 2025-09-18 | Baumeler Alfred |
Director, President |
Award↑
Filing footnotes — Stock option (right to buy) (Direct)
One-third (1/3) of this option grant vests on the first anniversary of the date of grant, and the remaining two-thirds (2/3) vest in equal monthly installments over the following twenty-four (24) months, subject to the reporting person's continued service with the Company. |
Stock option (right to buy)
|
150,000 |
| 2025-09-18 | Fickett Jaime |
Chief Financial Officer |
Award↑
Filing footnotes — Stock option (right to buy) (Direct)
One-third (1/3) of this option grant vests on the first anniversary of the date of grant, and the remaining two-thirds (2/3) vest in equal monthly installments over the following twenty-four (24) months, subject to the reporting person's continued service with the Company. |
Stock option (right to buy)
|
150,000 |
| 2025-07-30 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
|
Common Stock, par value $0.00001 per share
|
100 |
| 2025-07-29 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
Filing footnotes — Common Stock, par value $0.00001 per share (Direct)
The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Synergy CHC Corp., any security holder of Synergy CHC Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (21) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.653 to $3.689, inclusive. |
Common Stock, par value $0.00001 per share
|
250 |
| 2025-07-25 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
Filing footnotes — Common Stock, par value $0.00001 per share (Direct)
The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Synergy CHC Corp., any security holder of Synergy CHC Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (21) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.830 to $3.935, inclusive. |
Common Stock, par value $0.00001 per share
|
350 |
| 2025-07-24 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
Filing footnotes — Common Stock, par value $0.00001 per share (Direct)
The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Synergy CHC Corp., any security holder of Synergy CHC Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (21) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.761 to $3.910, inclusive. |
Common Stock, par value $0.00001 per share
|
300 |
| 2025-07-22 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
Filing footnotes — Common Stock, par value $0.00001 per share (Direct)
The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Synergy CHC Corp., any security holder of Synergy CHC Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (21) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.465 to $3.583, inclusive. |
Common Stock, par value $0.00001 per share
|
300 |
| 2025-07-11 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
Filing footnotes — Common Stock, par value $0.00001 per share (Direct)
The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Synergy CHC Corp., any security holder of Synergy CHC Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (21) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.137 to $3.277, inclusive. |
Common Stock, par value $0.00001 per share
|
750 |
| 2025-07-10 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
Filing footnotes — Common Stock, par value $0.00001 per share (Direct)
The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Synergy CHC Corp., any security holder of Synergy CHC Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (21) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.147 to $3.230, inclusive. |
Common Stock, par value $0.00001 per share
|
1,400 |
| 2025-07-09 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
Filing footnotes — Common Stock, par value $0.00001 per share (Direct)
The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Synergy CHC Corp., any security holder of Synergy CHC Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (21) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.087 to $3.341, inclusive. |
Common Stock, par value $0.00001 per share
|
400 |
| 2025-07-08 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
Filing footnotes — Common Stock, par value $0.00001 per share (Direct)
The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Synergy CHC Corp., any security holder of Synergy CHC Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (21) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.336 to $3.370, inclusive. |
Common Stock, par value $0.00001 per share
|
800 |
| 2025-07-07 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
Filing footnotes — Common Stock, par value $0.00001 per share (Direct)
The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Synergy CHC Corp., any security holder of Synergy CHC Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (21) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.240 to $3.327, inclusive. |
Common Stock, par value $0.00001 per share
|
700 |
| 2025-07-03 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
Filing footnotes — Common Stock, par value $0.00001 per share (Direct)
The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Synergy CHC Corp., any security holder of Synergy CHC Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (21) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.197 to $3.236, inclusive. |
Common Stock, par value $0.00001 per share
|
1,750 |
| 2025-07-02 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
Filing footnotes — Common Stock, par value $0.00001 per share (Direct)
The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Synergy CHC Corp., any security holder of Synergy CHC Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (21) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.118 to $3.274, inclusive. |
Common Stock, par value $0.00001 per share
|
3,750 |
| 2025-07-01 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
Filing footnotes — Common Stock, par value $0.00001 per share (Direct)
The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Synergy CHC Corp., any security holder of Synergy CHC Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (21) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.005 to $3.120, inclusive. |
Common Stock, par value $0.00001 per share
|
250 |
| 2025-06-30 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
Filing footnotes — Common Stock, par value $0.00001 per share (Direct)
The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Synergy CHC Corp., any security holder of Synergy CHC Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (21) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.575 to $2.860, inclusive. |
Common Stock, par value $0.00001 per share
|
2,600 |
| 2025-06-27 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
|
Common Stock, par value $0.00001 per share
|
100 |
| 2025-06-26 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
Filing footnotes — Common Stock, par value $0.00001 per share (Direct)
The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Synergy CHC Corp., any security holder of Synergy CHC Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (21) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.525 to $2.574, inclusive. |
Common Stock, par value $0.00001 per share
|
650 |
| 2025-06-24 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
Filing footnotes — Common Stock, par value $0.00001 per share (Direct)
The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Synergy CHC Corp., any security holder of Synergy CHC Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (21) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.551 to $2.688, inclusive. |
Common Stock, par value $0.00001 per share
|
600 |
| 2025-06-23 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
Filing footnotes — Common Stock, par value $0.00001 per share (Direct)
The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Synergy CHC Corp., any security holder of Synergy CHC Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (21) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.608 to $2.615, inclusive. |
Common Stock, par value $0.00001 per share
|
400 |
| 2025-06-20 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
Filing footnotes — Common Stock, par value $0.00001 per share (Direct)
The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Synergy CHC Corp., any security holder of Synergy CHC Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (21) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.200 to $2.750, inclusive. |
Common Stock, par value $0.00001 per share
|
10,300 |
| 2025-06-18 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
Filing footnotes — Common Stock, par value $0.00001 per share (Direct)
The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Synergy CHC Corp., any security holder of Synergy CHC Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (21) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.210 to $2.240, inclusive. |
Common Stock, par value $0.00001 per share
|
600 |
| 2025-06-17 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
|
Common Stock, par value $0.00001 per share
|
100 |
| 2025-06-16 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
Filing footnotes — Common Stock, par value $0.00001 per share (Direct)
The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Synergy CHC Corp., any security holder of Synergy CHC Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (21) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.080 to $2.340, inclusive. |
Common Stock, par value $0.00001 per share
|
450 |
| 2025-06-13 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
|
Common Stock, par value $0.00001 per share
|
100 |
| 2025-06-11 | Knight Therapeutics Inc |
Insider |
Buy↑
Filing footnotes — Pre-Funded Common Stock Purchase Warrant (Indirect)
The Pre-Funded Common Stock Purchase Warrants (the "Warrants") are exercisable by the holder at any time on or after June 11, 2025 at an exercise price equal to $0.00001 per share, subject to adjustments as provided under the terms of the Warrant, subject to a post-exercise beneficial ownership limitation of 19.90% ("Beneficial Ownership Limitation"). The Warrants will expire on June 11, 2026 with automatic extensions of one year each in case the Warrants have not been exercised in full due to the Beneficial Ownership Limitation. The 428,570 Warrants are held by Knight Therapeutics International S.A. ("Knight Subsidiary"), a wholly-owned subsidiary of the Reporting Person. The Reporting Person is the sole owner of Knight Subsidiary and, as a result, may be deemed the beneficial owner for purposes of the U.S. Securities Exchange Act of 1934 ("Act") of any securities of Issuer beneficially owned by Knight Subsidiary. The Reporting Person disclaims beneficial ownership over all of the securities beneficially owned by Knight Subsidiary, other than for the purpose of determining obligations under the Act, and the filing of this Form 4 shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for any other purpose. |
Pre-Funded Common Stock Purchase Warrant
(I)
|
428,570 |
| 2025-06-11 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
Filing footnotes — Common Stock, par value $0.00001 per share (Direct)
The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Synergy CHC Corp., any security holder of Synergy CHC Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (21) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.173 to $2.198, inclusive. |
Common Stock, par value $0.00001 per share
|
900 |
| 2025-06-10 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
Filing footnotes — Common Stock, par value $0.00001 per share (Direct)
The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Synergy CHC Corp., any security holder of Synergy CHC Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.110 to $2.200, inclusive. |
Common Stock, par value $0.00001 per share
|
1,200 |
| 2025-06-09 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
Filing footnotes — Common Stock, par value $0.00001 per share (Direct)
The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Synergy CHC Corp., any security holder of Synergy CHC Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.110 to $2.180, inclusive. |
Common Stock, par value $0.00001 per share
|
700 |
| 2025-06-05 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
Filing footnotes — Common Stock, par value $0.00001 per share (Direct)
The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Synergy CHC Corp., any security holder of Synergy CHC Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.990 to $2.070, inclusive. |
Common Stock, par value $0.00001 per share
|
800 |
| 2025-06-04 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
Filing footnotes — Common Stock, par value $0.00001 per share (Direct)
The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Synergy CHC Corp., any security holder of Synergy CHC Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.026 to $2.130, inclusive. |
Common Stock, par value $0.00001 per share
|
1,600 |
| 2025-06-03 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
Filing footnotes — Common Stock, par value $0.00001 per share (Direct)
The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Synergy CHC Corp., any security holder of Synergy CHC Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.738 to $1.888, inclusive. |
Common Stock, par value $0.00001 per share
|
9,400 |
| 2025-06-02 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
Filing footnotes — Common Stock, par value $0.00001 per share (Direct)
The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Synergy CHC Corp., any security holder of Synergy CHC Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.714 to $1.760, inclusive. |
Common Stock, par value $0.00001 per share
|
2,400 |
| 2025-05-15 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
Filing footnotes — Common Stock, par value $0.00001 per share (Direct)
The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Synergy CHC Corp., any security holder of Synergy CHC Corp., or the staff of the Securities and Ex-change Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (9) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.116 to $2.180, inclusive. |
Common Stock, par value $0.00001 per share
|
500 |
| 2025-05-14 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
|
Common Stock, par value $0.00001 per share
|
100 |
| 2025-05-13 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
Filing footnotes — Common Stock, par value $0.00001 per share (Direct)
The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Synergy CHC Corp., any security holder of Synergy CHC Corp., or the staff of the Securities and Ex-change Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (9) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.821 to $1.968, inclusive. |
Common Stock, par value $0.00001 per share
|
1,000 |
| 2025-05-12 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
Filing footnotes — Common Stock, par value $0.00001 per share (Direct)
The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Synergy CHC Corp., any security holder of Synergy CHC Corp., or the staff of the Securities and Ex-change Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (9) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.827 to $1.830, inclusive. |
Common Stock, par value $0.00001 per share
|
300 |
| 2025-05-06 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
|
Common Stock, par value $0.00001 per share
|
100 |
| 2025-05-05 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
Filing footnotes — Common Stock, par value $0.00001 per share (Direct)
The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Synergy CHC Corp., any security holder of Synergy CHC Corp., or the staff of the Securities and Ex-change Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (9) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.043 to $2.174, inclusive. |
Common Stock, par value $0.00001 per share
|
800 |
| 2025-05-02 | Ross Jack |
Director, CEO and Chairman, 10% Owner |
Buy↑
Filing footnotes — Common Stock, par value $0.00001 per share (Direct)
The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Synergy CHC Corp., any security holder of Synergy CHC Corp., or the staff of the Securities and Ex-change Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (9) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.025 to $2.093, inclusive. |
Common Stock, par value $0.00001 per share
|
900 |